Clinic
Women & Infants Hospital of Rhode Island
Women & Infants Hospital of Rhode Island was paid $132.16M by Medicaid between Jan 2018 and Dec 2024, across 338 billing codes. Its largest line is 99284, emergency room visit (serious) — 5.9% of everything it billed.
33Billing provider infoWOMEN & INFANTS HOSPITAL OF RHODE ISLAND
PROVIDENCE, RI 02905
PROVIDENCE, RI 02905
33aNPI1447233788assigned 11/21/2005
33bProvider typeAmbulatory Family Planning Facility
28Total paid$132.16M
24GClaims1,360,699
24DCodes billed338
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 282,104 | $20.22M | |
| 2019 | 299,687 | $26.26M | |
| 2020 | 149,548 | $16.31M | |
| 2021 | 169,263 | $17.15M | |
| 2022 | 155,601 | $17.11M | |
| 2023 | 165,993 | $18.27M | |
| 2024incomplete | 138,503 | $16.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.9% | 9,479 | 7,890 | $7.85M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.7% | 46,275 | 39,114 | $6.26M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.3% | 45,547 | 38,446 | $4.38M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.2% | 24,082 | 19,286 | $4.17M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.6% | 7,876 | 3,714 | $3.42M |
| 76818 | 2.5% | 12,995 | 4,325 | $3.27M | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.3% | 31,892 | 27,336 | $3.05M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.2% | 45,658 | 38,566 | $2.87M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 16,824 | 5,821 | $2.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 2,529 | 2,277 | $2.45M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 7,550 | 3,264 | $2.39M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.8% | 4,652 | 3,612 | $2.39M |
326 more codes
| G0378 | Hospital observation service, per hour | 1.8% | 1,402 | $2.34M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 61,718 | $2.19M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.6% | 10,667 | $2.09M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.6% | 61,794 | $2.08M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.6% | 21,407 | $2.08M |
| 99218 | 1.6% | 1,297 | $2.08M | |
| 59025 | Fetal non-stress test | 1.5% | 9,721 | $1.94M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.4% | 29,048 | $1.90M |
| 76830 | Ultrasound, transvaginal | 1.3% | 6,702 | $1.77M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 12,757 | $1.66M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.2% | 6,569 | $1.59M |
| 86803 | 1.2% | 18,718 | $1.59M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 19,017 | $1.59M |
| 87480 | 1.1% | 21,175 | $1.51M | |
| 86850 | 1.1% | 25,772 | $1.48M | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.1% | 6,251 | $1.47M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 16,166 | $1.36M |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 115 | $1.25M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 15,360 | $1.22M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 6,470 | $1.21M |
| 86780 | <1% | 27,725 | $1.20M | |
| 76801 | <1% | 8,181 | $1.14M | |
| 86901 | <1% | 25,880 | $1.12M | |
| 86900 | <1% | 25,870 | $1.12M | |
| 87660 | <1% | 21,054 | $1.11M | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 8,539 | $1.11M |
| 84702 | <1% | 15,824 | $1.08M | |
| 87340 | <1% | 18,428 | $1.05M | |
| 87150 | <1% | 12,518 | $1.03M | |
| 86762 | <1% | 12,389 | $979K | |
| 81001 | <1% | 26,718 | $959K | |
| 87510 | <1% | 17,913 | $908K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,394 | $902K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,246 | $827K |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 177 | $777K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,622 | $776K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,877 | $747K |
| 96417 | <1% | 2,825 | $739K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,936 | $732K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,190 | $697K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,728 | $662K |
| 81025 | <1% | 7,750 | $644K | |
| 82728 | <1% | 8,394 | $640K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,646 | $639K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,619 | $638K |
| 80061 | Lipid panel | <1% | 9,999 | $613K |
| 86481 | <1% | 3,924 | $583K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,775 | $535K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 784 | $505K |
| 82105 | <1% | 13,005 | $490K | |
| 76642 | <1% | 5,194 | $486K | |
| 87088 | <1% | 12,843 | $469K | |
| 86787 | <1% | 5,005 | $445K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,832 | $444K |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 642 | $437K |
| 77066 | Tomosynthesis, mammo | <1% | 2,638 | $430K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,970 | $430K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,103 | $425K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,894 | $418K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,302 | $412K |
| 96415 | <1% | 1,508 | $410K | |
| 82962 | <1% | 2,601 | $398K | |
| 82677 | <1% | 5,989 | $385K | |
| 86480 | <1% | 3,592 | $373K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,017 | $369K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,593 | $369K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 504 | $353K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,936 | $346K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,745 | $345K |
| J3490 | Unclassified drugs | <1% | 3,558 | $325K |
| 77065 | Tomosynthesis, mammo | <1% | 2,417 | $318K |
| 88307 | <1% | 2,995 | $317K | |
| 82565 | <1% | 9,013 | $311K | |
| 80050 | General health panel | <1% | 3,159 | $301K |
| 80076 | <1% | 9,903 | $296K | |
| 96040 | <1% | 3,890 | $293K | |
| 76813 | <1% | 2,427 | $289K | |
| 58661 | <1% | 99 | $285K | |
| 85027 | <1% | 6,793 | $285K | |
| 80053 | Comprehensive metabolic panel | <1% | 7,384 | $283K |
| 87210 | <1% | 5,744 | $281K | |
| 82950 | <1% | 11,159 | $280K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 7,070 | $268K |
| 82607 | <1% | 4,249 | $265K | |
| 88342 | <1% | 1,493 | $262K | |
| 76825 | <1% | 792 | $262K | |
| 83735 | <1% | 6,349 | $260K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,010 | $258K |
| 83021 | <1% | 3,313 | $256K | |
| 86870 | <1% | 1,139 | $252K | |
| 76820 | <1% | 2,783 | $248K | |
| 87186 | <1% | 5,358 | $245K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,674 | $239K |
| 96402 | <1% | 2,298 | $237K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,665 | $229K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,764 | $226K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,017 | $224K |
| 87070 | <1% | 5,648 | $220K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,486 | $217K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,718 | $214K |
| 81229 | <1% | 151 | $211K | |
| 84450 | <1% | 6,561 | $200K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 233 | $196K |
| 84100 | <1% | 5,480 | $195K | |
| 88141 | <1% | 4,990 | $193K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 205 | $193K |
| 83550 | <1% | 4,053 | $191K | |
| 81003 | <1% | 3,665 | $188K | |
| 58571 | <1% | 68 | $187K | |
| 86336 | <1% | 5,993 | $182K | |
| 92579 | <1% | 1,977 | $181K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,417 | $181K |
| 83001 | <1% | 2,197 | $174K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,122 | $171K |
| 51729 | <1% | 396 | $171K | |
| 59430 | <1% | 1,243 | $170K | |
| 83020 | <1% | 1,166 | $167K | |
| 82570 | <1% | 5,691 | $166K | |
| 84460 | <1% | 4,893 | $166K | |
| 84146 | <1% | 1,932 | $161K | |
| 84439 | <1% | 4,071 | $159K | |
| 92587 | <1% | 1,748 | $159K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,631 | $156K |
| 58300 | <1% | 463 | $155K | |
| 83615 | <1% | 5,266 | $152K | |
| 87077 | <1% | 4,550 | $149K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,092 | $149K |
| 88341 | <1% | 860 | $148K | |
| 80051 | <1% | 4,126 | $143K | |
| 93975 | <1% | 814 | $142K | |
| 82670 | <1% | 915 | $141K | |
| 84156 | <1% | 5,520 | $140K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 197 | $134K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,821 | $133K |
| 36416 | <1% | 304 | $131K | |
| 82951 | <1% | 2,589 | $126K | |
| 84163 | <1% | 3,954 | $123K | |
| 99429 | <1% | 124 | $116K | |
| A4315 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way, all silicone | <1% | 647 | $115K |
| 85610 | <1% | 2,477 | $113K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,027 | $112K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,234 | $111K |
| 58301 | <1% | 350 | $110K | |
| 84520 | <1% | 4,433 | $109K | |
| 81002 | <1% | 9,292 | $109K | |
| 82746 | <1% | 1,709 | $108K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 356 | $108K |
| 82310 | <1% | 4,295 | $107K | |
| 96367 | <1% | 624 | $107K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,097 | $97K |
| 93325 | <1% | 745 | $97K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,165 | $93K |
| 97802 | <1% | 788 | $91K | |
| 96112 | <1% | 453 | $90K | |
| 76827 | <1% | 737 | $90K | |
| 86304 | <1% | 1,415 | $88K | |
| 92567 | <1% | 2,257 | $88K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 85 | $88K |
| 82248 | <1% | 5,937 | $88K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 345 | $80K |
| 86706 | <1% | 1,496 | $80K | |
| 85730 | <1% | 1,323 | $79K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 181 | $79K |
| 19083 | <1% | 90 | $79K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 372 | $78K |
| 82247 | <1% | 5,668 | $77K | |
| 84403 | <1% | 949 | $76K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 443 | $74K |
| 98960 | <1% | 488 | $72K | |
| 86920 | <1% | 607 | $72K | |
| 83013 | <1% | 560 | $71K | |
| 84703 | <1% | 1,121 | $71K | |
| 84481 | <1% | 638 | $67K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 181 | $64K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 475 | $63K |
| 96376 | <1% | 618 | $61K | |
| 51797 | <1% | 341 | $59K | |
| C9463 | Injection, aprepitant, 1 mg | <1% | 182 | $58K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 832 | $58K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 491 | $57K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 660 | $57K |
| 76641 | <1% | 270 | $52K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,261 | $52K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 612 | $52K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 522 | $50K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 860 | $49K |
| 82465 | <1% | 2,137 | $48K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 396 | $46K |
| 84550 | <1% | 1,944 | $45K | |
| 84402 | <1% | 491 | $43K | |
| 82947 | <1% | 2,325 | $41K | |
| 97803 | <1% | 571 | $39K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 186 | $39K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 63 | $39K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 397 | $37K |
| 77080 | <1% | 459 | $37K | |
| 83690 | <1% | 676 | $35K | |
| 86140 | <1% | 1,422 | $31K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 766 | $30K |
| 87522 | Neg quan hep c or qual rna | <1% | 149 | $30K |
| 82043 | <1% | 1,734 | $30K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 418 | $30K |
| 81479 | Unlisted molecular pathology procedure | <1% | 73 | $29K |
| 87255 | <1% | 411 | $28K | |
| 82378 | <1% | 391 | $28K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 743 | $28K |
| 82952 | <1% | 2,320 | $27K | |
| 82239 | <1% | 693 | $26K | |
| 77062 | <1% | 128 | $25K | |
| 85652 | <1% | 1,701 | $25K | |
| 86923 | <1% | 61 | $24K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 324 | $22K |
| 87081 | <1% | 730 | $22K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 192 | $21K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 140 | $20K |
| 83516 | <1% | 503 | $19K | |
| 57288 | <1% | 13 | $19K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 271 | $18K |
| 85018 | <1% | 457 | $18K | |
| 82784 | <1% | 298 | $18K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 135 | $17K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 111 | $17K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 252 | $17K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 237 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 162 | $16K |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 209 | $15K |
| 86376 | <1% | 179 | $15K | |
| 90686 | <1% | 394 | $15K | |
| 89060 | <1% | 280 | $14K | |
| 92588 | <1% | 130 | $14K | |
| 88302 | <1% | 111 | $14K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 12 | $14K |
| 86300 | <1% | 227 | $13K | |
| 88300 | <1% | 27 | $13K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 60 | $12K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 137 | $12K |
| 90674 | <1% | 306 | $11K | |
| 86696 | <1% | 248 | $11K | |
| 83002 | <1% | 173 | $10K | |
| 86618 | <1% | 198 | $10K | |
| 76376 | <1% | 84 | $10K | |
| 82550 | <1% | 366 | $10K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 35 | $10K |
| 86704 | <1% | 238 | $10K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 85 | $10K |
| 86695 | <1% | 249 | $10K | |
| 83014 | <1% | 545 | $9K | |
| 82627 | <1% | 114 | $9K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 222 | $9K |
| 84478 | <1% | 260 | $9K | |
| 77061 | <1% | 60 | $8K | |
| 86694 | <1% | 177 | $8K | |
| 87075 | <1% | 170 | $8K | |
| 87581 | <1% | 68 | $8K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 52 | $7K |
| 87205 | <1% | 255 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 51 | $7K |
| 92550 | <1% | 200 | $6K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 54 | $6K |
| 83986 | <1% | 504 | $6K | |
| 83540 | <1% | 168 | $6K | |
| 90480 | <1% | 132 | $6K | |
| 86039 | <1% | 135 | $5K | |
| 92558 | <1% | 130 | $5K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 110 | $5K |
| 83721 | <1% | 188 | $5K | |
| 76882 | <1% | 87 | $5K | |
| 85046 | <1% | 249 | $5K | |
| 58340 | <1% | 40 | $5K | |
| 99152 | <1% | 51 | $5K | |
| 93976 | <1% | 34 | $5K | |
| 86709 | <1% | 114 | $5K | |
| 99201 | <1% | 112 | $4K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 46 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 164 | $4K |
| 77049 | <1% | 12 | $4K | |
| 87430 | <1% | 147 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 40 | $4K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 275 | $4K |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 14 | $4K |
| 96523 | <1% | 85 | $4K | |
| 85384 | <1% | 269 | $3K | |
| 52000 | <1% | 13 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 167 | $3K |
| 87147 | <1% | 146 | $3K | |
| 0001A | <1% | 46 | $3K | |
| 85651 | <1% | 168 | $3K | |
| 51725 | <1% | 14 | $3K | |
| 87517 | <1% | 33 | $3K | |
| 84144 | <1% | 25 | $3K | |
| 57454 | <1% | 13 | $2K | |
| 87486 | <1% | 26 | $2K | |
| 86735 | <1% | 29 | $2K | |
| 83970 | <1% | 13 | $2K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 117 | $2K |
| 84425 | <1% | 36 | $2K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 65 | $2K |
| 11982 | <1% | 12 | $2K | |
| 86765 | <1% | 27 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25 | $2K |
| 84436 | <1% | 91 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $2K |
| 92585 | <1% | 13 | $2K | |
| 0002A | <1% | 39 | $2K | |
| 92593 | <1% | 45 | $2K | |
| 58100 | <1% | 12 | $1K | |
| 86705 | <1% | 26 | $1K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 16 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 20 | $1K |
| 84075 | <1% | 52 | $1K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 191 | $1K |
| 83520 | <1% | 16 | $960.14 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 273 | $912.22 |
| 82120 | <1% | 27 | $766.14 | |
| 85014 | <1% | 48 | $735.52 | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 32 | $725.73 |
| 82652 | <1% | 13 | $669.53 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 22 | $642.98 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 121 | $640.55 |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 15 | $547.68 |
| 84132 | <1% | 47 | $488.87 | |
| 86431 | <1% | 36 | $457.80 | |
| 82150 | <1% | 17 | $299.59 | |
| 90661 | <1% | 19 | $109.64 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 39 | $16.21 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICCI, THOMAS (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Wih Faculty Physicians, INC | New Bedford, MA | $1.70M |
| Women & Infants Hospital of Ri | Providence, RI | $85.92 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.